Clinical Reviews in Allergy & Immunology

, Volume 55, Issue 3, pp 239–253 | Cite as

Autoimmunity in 2017

  • Carlo SelmiEmail author


The number of peer-reviewed articles published during the 2017 solar year and retrieved using the “autoimmunity” key word increased significantly compared to 2016 while maintaining a stable share within the immunology field, following years with alternated fortunes. A detailed arbitrary analysis of the published articles in leading immunology and autoimmunity journals provides a privileged viewpoint on the current trends of research from both basic and clinical studies. Indeed, we are observing that major steps forward are found for rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, among others. In particular, the new data on pregnancy success in lupus or biomarkers in systemic sclerosis are believed to change our management of these systemic conditions. In the case of rheumatoid arthritis, we have obtained data with significant implications in the understanding of the disease pathogenesis (as in the case of platelets), disease phenotyping, and new treatment options. Furthermore, the exponential growth of treatment options for cancer based on immune checkpoint modulation is paralleled by the need to address the potential autoimmunity side effects while taking advantage of new information obtained in paraneoplastic autoimmune conditions. Cumulatively, 2017 has been a very exciting year for autoimmune diseases, and we foresee that most of the data discussed herein will be followed by more extensive studies in the upcoming months.


Immune tolerance Immune checkpoint inhibitors Autoantibody Platelet Th17 


Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflict of interest.

Ethical Approval and Informed Consent

The present article is a review; thus, no informed consent was obtained.


  1. 1.
    Anquetil F, Sabouri S, Thivolet C, Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, Schneider D, Castillo E, Lajevardi Y, von Herrath MG (2017) Alpha cells, the main source of IL-1beta in human pancreas. J Autoimmun 81:68–73PubMedPubMedCentralGoogle Scholar
  2. 2.
    Hull CM, Nickolay LE, Estorninho M, Richardson MW, Riley JL, Peakman M, Maher J, Tree TIM (2017) Generation of human islet-specific regulatory T cells by TCR gene transfer. J Autoimmun 79:63–73PubMedGoogle Scholar
  3. 3.
    Kaminitz A, Ash S, Askenasy N (2017) Neutralization versus reinforcement of proinflammatory cytokines to arrest autoimmunity in type 1 diabetes. Clin Rev Allergy Immunol 52(3):460–472PubMedGoogle Scholar
  4. 4.
    Kracht MJ et al (2017) Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med 23(4):501–507PubMedGoogle Scholar
  5. 5.
    Kuhn C, Rezende RM, da Cunha AP, Valette F, Quintana FJ, Chatenoud L, Weiner HL (2017) Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. J Autoimmun 76:115–122PubMedGoogle Scholar
  6. 6.
    Li CW, Osman R, Menconi F, Concepcion ES, Tomer Y (2017) Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 76:1–9PubMedGoogle Scholar
  7. 7.
    Li YY, Pearson JA, Chao C, Peng J, Zhang X, Zhou Z, Liu Y, Wong FS, Wen L (2017) Nucleotide-binding oligomerization domain-containing protein 2 (Nod2) modulates T1DM susceptibility by gut microbiota. J Autoimmun 82:85–95PubMedGoogle Scholar
  8. 8.
    Lombardi A, Tomer Y (2017) Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun 80:48–55PubMedPubMedCentralGoogle Scholar
  9. 9.
    Marino E et al (2017) Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat Immunol 18(5):552–562PubMedGoogle Scholar
  10. 10.
    Ryden AK et al (2017) Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes. J Autoimmun 84:65–74PubMedGoogle Scholar
  11. 11.
    Wang Z, Xie Z, Lu Q, Chang C, Zhou Z (2017) Beyond genetics: what causes type 1 diabetes. Clin Rev Allergy Immunol 52(2):273–286PubMedGoogle Scholar
  12. 12.
    Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K (2017) An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun 78:11–18PubMedGoogle Scholar
  13. 13.
    Zerif E, Maalem A, Gaudreau S, Guindi C, Ramzan M, Véroneau S, Gris D, Stankova J, Rola-Pleszczynski M, Mourad W, Dupuis G, Amrani A (2017) Constitutively active Stat5b signaling confers tolerogenic functions to dendritic cells of NOD mice and halts diabetes progression. J Autoimmun 76:63–74PubMedGoogle Scholar
  14. 14.
    Harbige J, Eichmann M, Peakman M (2017) New insights into non-conventional epitopes as T cell targets: the missing link for breaking immune tolerance in autoimmune disease? J Autoimmun 84:12–20PubMedGoogle Scholar
  15. 15.
    Afzali AM, Ruck T, Wiendl H, Meuth SG (2017) Animal models in idiopathic inflammatory myopathies: how to overcome a translational roadblock? Autoimmun Rev 16(5):478–494PubMedGoogle Scholar
  16. 16.
    Bartoloni E, Gonzalez-Gay MA, Scirè C, Castaneda S, Gerli R, Lopez-Longo FJ, Martinez-Barrio J, Govoni M, Furini F, Pina T, Iannone F, Giannini M, Nuño L, Quartuccio L, Ortego-Centeno N, Alunno A, Specker C, Montecucco C, Triantafyllias K, Balduzzi S, Sifuentes-Giraldo WA, Paolazzi G, Bravi E, Schwarting A, Pellerito R, Russo A, Selmi C, Saketkoo LA, Fusaro E, Parisi S, Pipitone N, Franceschini F, Cavazzana I, Neri R, Barsotti S, Codullo V, Cavagna L (2017) Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: results from a multicenter, international and retrospective study. Autoimmun Rev 16(3):253–257PubMedGoogle Scholar
  17. 17.
    Cavagna L, Monti S, Caporali R, Gatto M, Iaccarino L, Doria A (2017) How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmun Rev 16(10):999–1007PubMedGoogle Scholar
  18. 18.
    Cavagna L et al (2017) Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS Collaborative Group. Clin Rev Allergy Immunol 52(1):71–80PubMedGoogle Scholar
  19. 19.
    Cavazzana I, Fredi M, Selmi C, Tincani A, Franceschini F (2017) The clinical and histological spectrum of idiopathic inflammatory myopathies. Clin Rev Allergy Immunol 52(1):88–98PubMedGoogle Scholar
  20. 20.
    Ceribelli A, de Santis M, Isailovic N, Gershwin ME, Selmi C (2017) The immune response and the pathogenesis of idiopathic inflammatory myositis: a critical review. Clin Rev Allergy Immunol 52(1):58–70PubMedGoogle Scholar
  21. 21.
    Cucchiari D, Angelini C (2017) Renal involvement in idiopathic inflammatory myopathies. Clin Rev Allergy Immunol 52(1):99–107PubMedGoogle Scholar
  22. 22.
    Day J, Otto S, Proudman S, Hayball JD, Limaye V (2017) Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies. Autoimmun Rev 16(1):87–95PubMedGoogle Scholar
  23. 23.
    Gao S, Luo H, Zhang H, Zuo X, Wang L, Zhu H (2017) Using multi-omics methods to understand dermatomyositis/polymyositis. Autoimmun Rev 16(10):1044–1048PubMedGoogle Scholar
  24. 24.
    Gunawardena H (2017) The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol 52(1):45–57PubMedGoogle Scholar
  25. 25.
    Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T (2017) Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun 77:116–122PubMedGoogle Scholar
  26. 26.
    Lu X, Tang Q, Lindh M, Dastmalchi M, Alexanderson H, Popovic Silwerfeldt K, Agerberth B, Lundberg IE, Wick C (2017) The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. J Autoimmun 78:46–56PubMedGoogle Scholar
  27. 27.
    Mainetti C, Terziroli Beretta-Piccoli B, Selmi C (2017) Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol 53(3):337–356PubMedGoogle Scholar
  28. 28.
    Moghadam-Kia S, Oddis CV, Aggarwal R (2017) Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics. Clin Rev Allergy Immunol 52(1):81–87PubMedPubMedCentralGoogle Scholar
  29. 29.
    Pagnini I, Vitale A, Selmi C, Cimaz R, Cantarini L (2017) Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms. Clin Rev Allergy Immunol 52(1):34–44PubMedGoogle Scholar
  30. 30.
    Santos E, Coutinho E, Martins da Silva A, Marinho A, Vasconcelos C, Taipa R, Pires MM, Gonçalves G, Lopes C, Leite MI (2017) Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: report of four cases and literature review. Autoimmun Rev 16(6):644–649PubMedGoogle Scholar
  31. 31.
    Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1–19PubMedPubMedCentralGoogle Scholar
  32. 32.
    Suzuki S, Uruha A, Suzuki N, Nishino I (2017) Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology. Autoimmun Rev 16(7):693–700PubMedGoogle Scholar
  33. 33.
    Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ (2017) Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 84:55–64PubMedPubMedCentralGoogle Scholar
  34. 34.
    Tiniakou E, Mammen AL (2017) Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52(1):20–33PubMedGoogle Scholar
  35. 35.
    Espitia-Thibault A, Masseau A, Néel A, Espitia O, Toquet C, Mussini JM, Hamidou M (2017) Sjogren’s syndrome-associated myositis with germinal centre-like structures. Autoimmun Rev 16(2):154–158PubMedGoogle Scholar
  36. 36.
    Fujimura T, Fujimoto T, Itaya-Hironaka A, Miyaoka T, Yoshimoto K, Sakuramoto-Tsuchida S, Yamauchi A, Takeda M, Tsujinaka H, Tanaka Y, Takasawa S (2017) Significance of interleukin-6/STAT pathway for the gene expression of REG Ialpha, a new autoantigen in Sjogren’s syndrome patients, in salivary duct epithelial cells. Clin Rev Allergy Immunol 52(3):351–363PubMedGoogle Scholar
  37. 37.
    Garcia-Carrasco M, Jiménez-Herrera EA, Gálvez-Romero JL, de Lara LV, Mendoza-Pinto C, Etchegaray-Morales I, Munguía-Realpozo P, Ruíz-Argüelles A, Jose R, Vera-Recabarren M, Cervera R (2017) Vitamin D and Sjogren syndrome. Autoimmun Rev 16(6):587–593PubMedGoogle Scholar
  38. 38.
    Generali E, Costanzo A, Mainetti C, Selmi C (2017) Cutaneous and mucosal manifestations of Sjogren’s syndrome. Clin Rev Allergy Immunol 53(3):357–370PubMedGoogle Scholar
  39. 39.
    Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, Kroese FGM (2017) FcRL4(+) B-cells in salivary glands of primary Sjogren’s syndrome patients. J Autoimmun 81:90–98PubMedGoogle Scholar
  40. 40.
    Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome. Autoimmun Rev 16(1):48–54PubMedGoogle Scholar
  41. 41.
    Chen Y, Chauhan SK, Tan X, Dana R (2017) Interleukin-7 and -15 maintain pathogenic memory Th17 cells in autoimmunity. J Autoimmun 77:96–103PubMedGoogle Scholar
  42. 42.
    Vanoni F, Lava SAG, Fossali EF, Cavalli R, Simonetti GD, Bianchetti MG, Bozzini MA, Agostoni C, Milani GP (2017) Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol 53(3):469–476PubMedGoogle Scholar
  43. 43.
    Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, Falk RJ, Charles Jennette J (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16(7):722–729PubMedGoogle Scholar
  44. 44.
    Andre R et al (2017) Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): report of 26 patients and review of the literature. Autoimmun Rev 16(9):963–969PubMedGoogle Scholar
  45. 45.
    Chasset F, Frances C (2017) Cutaneous manifestations of medium- and large-vessel vasculitis. Clin Rev Allergy Immunol 53(3):452–468PubMedGoogle Scholar
  46. 46.
    Ciccia F, Rizzo A, Ferrante A, Guggino G, Croci S, Cavazza A, Salvarani C, Triolo G (2017) New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev 16(7):675–683PubMedGoogle Scholar
  47. 47.
    Carvajal Alegria G, Gazeau P, Hillion S, Daïen CI, Cornec DYK (2017) Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases? Clin Rev Allergy Immunol 53(2):219–236PubMedGoogle Scholar
  48. 48.
    Cornec D, Berti A, Hummel A, Peikert T, Pers JO, Specks U (2017) Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. J Autoimmun 84:122–131PubMedGoogle Scholar
  49. 49.
    Danlos FX, Rossi GM, Blockmans D, Emmi G, Kronbichler A, Durupt S, Maynard C, Luca L, Garrouste C, Lioger B, Mourot-Cottet R, Dhote R, Arlet JB, Hanslik T, Rouvier P, Ebbo M, Puéchal X, Nochy D, Carlotti A, Mouthon L, Guillevin L, Vaglio A, Terrier B, French Vasculitis Study Group (2017) Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev 16(10):1036–1043PubMedGoogle Scholar
  50. 50.
    Frumholtz L, Laurent-Roussel S, Aumaître O, Maurier F, le Guenno G, Carlotti A, Dallot A, Kemeny JL, Antunes L, Froment N, Fraitag S, London J, Berezne A, Terris B, le Jeunne C, Mouthon L, Aractingi S, Guillevin L, Dupin N, Terrier B, French Vasculitis Study Group (2017) Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmun Rev 16(11):1138–1146PubMedGoogle Scholar
  51. 51.
    Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S, Monteiro RC, van Egmond M (2017) New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schonlein purpura). Autoimmun Rev 16(12):1246–1253PubMedGoogle Scholar
  52. 52.
    Hommada M, Mekinian A, Brillet PY, Abad S, Larroche C, Dhôte R, Fain O, Soussan M (2017) Aortitis in giant cell arteritis: diagnosis with FDG PET/CT and agreement with CT angiography. Autoimmun Rev 16(11):1131–1137PubMedGoogle Scholar
  53. 53.
    Abdul-Sater AA, Edilova MI, Clouthier DL, Mbanwi A, Kremmer E, Watts TH (2017) The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. Nat Immunol 18(1):26–35PubMedGoogle Scholar
  54. 54.
    Xue LJ, Wu R, du GL, Xu Y, Yuan KY, Feng ZC, Pan YL, Hu GY (2017) Effect and safety of TNF inhibitors in immunoglobulin-resistant Kawasaki disease: a meta-analysis. Clin Rev Allergy Immunol 52(3):389–400PubMedGoogle Scholar
  55. 55.
    Yilmaz I, Turk M, Bahcecioglu SN (2017) Classification of eosinophilic granulomatosis with polyangiitis phenotypes and treatment based on phenotypes. Autoimmun Rev 16(9):992–993PubMedGoogle Scholar
  56. 56.
    Kerstein A, Schüler S, Cabral-Marques O, Fazio J, Häsler R, Müller A, Pitann S, Moosig F, Klapa S, Haas C, Kabelitz D, Riemekasten G, Wolters S, Lamprecht P (2017) Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. J Autoimmun 78:79–91PubMedGoogle Scholar
  57. 57.
    Lefevre G, Ackermann F, Kahn JE (2017) Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? Autoimmun Rev 16(2):208–209PubMedGoogle Scholar
  58. 58.
    Legendre P, Régent A, Thiebault M, Mouthon L (2017) Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev 16(2):146–153PubMedGoogle Scholar
  59. 59.
    Lule S, Colpak AI, Balci-Peynircioglu B, Gursoy-Ozdemir Y, Peker S, Kalyoncu U, Can A, Tekin N, Demiralp D, Dalkara T (2017) Behcet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun 84:87–96PubMedGoogle Scholar
  60. 60.
    Martinez-Valle F et al (2017) IgG4-related disease: evidence from six recent cohorts. Autoimmun Rev 16(2):168–172PubMedGoogle Scholar
  61. 61.
    Marzano AV, Raimondo MG, Berti E, Meroni PL, Ingegnoli F (2017) Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol 53(3):428–438PubMedGoogle Scholar
  62. 62.
    Mirouse A, Barete S, Monfort JB, Resche-Rigon M, Bouyer AS, Comarmond C, Sène D, Domont F, Ferfar Y, Cacoub P, Saadoun D (2017) Ustekinumab for Behcet’s disease. J Autoimmun 82:41–46PubMedGoogle Scholar
  63. 63.
    Misra DP, Sharma A, Kadhiravan T, Negi VS (2017) A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 16(2):179–191PubMedGoogle Scholar
  64. 64.
    Regent A et al (2017) Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation. Autoimmun Rev 16(4):398–406PubMedGoogle Scholar
  65. 65.
    Restuccia G, Boiardi L, Cavazza A, Catanoso M, Macchioni P, Muratore F, Soriano A, Cimino L, Aldigeri R, Crescentini F, Pipitone N, Salvarani C (2017) Long-term remission in biopsy proven giant cell arteritis: a retrospective cohort study. J Autoimmun 77:39–44PubMedGoogle Scholar
  66. 66.
    Roccatello D (2017) “How I treat” autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 16(10):995–998PubMedGoogle Scholar
  67. 67.
    Salvarani C, Soriano A, Muratore F, Shoenfeld Y, Blockmans D (2017) Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? Autoimmun Rev 16(11):1125–1130PubMedGoogle Scholar
  68. 68.
    Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B (2017) Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 16(8):833–844PubMedGoogle Scholar
  69. 69.
    Savioli B, Abdulahad WH, Brouwer E, Kallenberg CGM, de Souza AWS (2017) Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? Autoimmun Rev 16(10):1071–1078PubMedGoogle Scholar
  70. 70.
    Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S (2017) Novel therapeutic targets for inflammatory bowel disease. J Autoimmun 85:103–116PubMedGoogle Scholar
  71. 71.
    Chua-Aguilera CJ, Moller B, Yawalkar N (2017) Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53(3):371–393PubMedGoogle Scholar
  72. 72.
    Boehncke WH, Brembilla NC (2017) Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy ImmunolGoogle Scholar
  73. 73.
    Greuter T, Navarini A, Vavricka SR (2017) Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 53(3):413–427PubMedGoogle Scholar
  74. 74.
    Hindryckx P, Laukens D, D’Amico F, Danese S (2017) Unmet needs in IBD: the case of fatigue. Clin Rev Allergy ImmunolGoogle Scholar
  75. 75.
    Lubrano E, De Socio A, and Perrotta FM (2017) Unmet needs in axial spondyloarthritis. Clin Rev Allergy ImmunolGoogle Scholar
  76. 76.
    Martin JC, Wolk K, Bériou G, Abidi A, Witte-Händel E, Louvet C, Kokolakis G, Drujont L, Dumoutier L, Renauld JC, Sabat R, Josien R (2017) Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation. J Immunol 198(9):3671–3678PubMedGoogle Scholar
  77. 77.
    Martin-Esteban A et al (2017) Separate effects of the ankylosing spondylitis associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome. J Autoimmun 79:28–38PubMedGoogle Scholar
  78. 78.
    McArdle A, Pennington S, and FitzGerald O (2017) Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs. Clin Rev Allergy ImmunolGoogle Scholar
  79. 79.
    Oka T, Sugaya M, Takahashi N, Takahashi T, Shibata S, Miyagaki T, Asano Y, Sato S (2017) CXCL17 attenuates Imiquimod-induced psoriasis-like skin inflammation by recruiting myeloid-derived suppressor cells and regulatory T cells. J Immunol 198(10):3897–3908PubMedGoogle Scholar
  80. 80.
    Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI (2017) Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev 16(1):55–63PubMedGoogle Scholar
  81. 81.
    Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI (2017) IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev 16(4):416–426PubMedGoogle Scholar
  82. 82.
    Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (2017) Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev 16(5):495–503PubMedGoogle Scholar
  83. 83.
    Pollock RA, Abji F, Gladman DD (2017) Epigenetics of psoriatic disease: a systematic review and critical appraisal. J Autoimmun 78:29–38PubMedGoogle Scholar
  84. 84.
    Prinz JC (2017) Autoimmune aspects of psoriasis: heritability and autoantigens. Autoimmun Rev 16(9):970–979PubMedGoogle Scholar
  85. 85.
    Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E (2017) Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 76:21–37PubMedGoogle Scholar
  86. 86.
    Robert M, Miossec P (2017) Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev 16(9):984–991PubMedGoogle Scholar
  87. 87.
    Sakkas LI, Bogdanos DP (2017) Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev 16(1):10–15PubMedPubMedCentralGoogle Scholar
  88. 88.
    Shabgah AG, Navashenaq JG, Shabgah OG, Mohammadi H, Sahebkar A (2017) Interleukin-22 in human inflammatory diseases and viral infections. Autoimmun Rev 16(12):1209–1218PubMedGoogle Scholar
  89. 89.
    Szentpetery A et al (2017) Effects of targeted therapies on the bone in arthritides. Autoimmun Rev 16(3):313–320PubMedGoogle Scholar
  90. 90.
    Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J, Bonifacio KM, Kunjravia N, Cueto I, Soung J, Fleischmann RM, Kivitz A, Lebwohl M, Nunez M, Woodson J, Smith SL, West RF, Berger M, Krueger JG, Ryan JL, Waksal SD (2017) Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol 198(10):3809–3814PubMedPubMedCentralGoogle Scholar
  91. 91.
    Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Gershwin ME, Leung PSC (2017) Common variable immunodeficiency and liver involvement. Clin Rev Allergy ImmunolGoogle Scholar
  92. 92.
    Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J (2017) Defective IL-4 signaling in T cells defines severe common variable immunodeficiency. J Autoimmun 81:110–119PubMedGoogle Scholar
  93. 93.
    Vignesh P, Rawat A, Singh S (2017) An update on the use of Immunomodulators in primary immunodeficiencies. Clin Rev Allergy Immunol 52(2):287–303PubMedGoogle Scholar
  94. 94.
    Wong GK, Heather JM, Barmettler S, Cobbold M (2017) Immune dysregulation in immunodeficiency disorders: the role of T-cell receptor sequencing. J Autoimmun 80:1–9PubMedGoogle Scholar
  95. 95.
    Dvir R, Sautto GA, Mancini N, Racca S, Diotti RA, Clementi M, Memoli M (2017) Autoimmune hepatitis and occult HCV infection: a prospective single-centre clinical study. Autoimmun Rev 16(3):323–325PubMedGoogle Scholar
  96. 96.
    Hardtke-Wolenski M, Dywicki J, Fischer K, Hapke M, Sievers M, Schlue J, Anderson MS, Taubert R, Noyan F, Manns MP, Jaeckel E (2017) The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. J Autoimmun 78:39–45PubMedGoogle Scholar
  97. 97.
    Lian M, Li B, Xiao X, Yang Y, Jiang P, Yan L, Sun C, Zhang J, Wei Y, Li Y, Chen W, Jiang X, Miao Q, Chen X, Qiu D, Sheng L, Hua J, Tang R, Wang Q, Eric Gershwin M, Ma X (2017) Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone. Autoimmun Rev 16(8):875–882PubMedGoogle Scholar
  98. 98.
    Terziroli Beretta-Piccoli B, Invernizzi P, Gershwin ME, Mainetti C (2017) Skin manifestations associated with autoimmune liver diseases: a systematic review. Clin Rev Allergy Immunol 53(3):394–412PubMedGoogle Scholar
  99. 99.
    Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X (2017) The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review. Clin Rev Allergy Immunol 52(3):424–435PubMedGoogle Scholar
  100. 100.
    Chung BK, Guevel BT, Reynolds GM, Gupta Udatha DBRK, Henriksen EKK, Stamataki Z, Hirschfield GM, Karlsen TH, Liaskou E (2017) Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. J Autoimmun 77:45–54PubMedGoogle Scholar
  101. 101.
    Li Y, Tang R, Leung PSC, Gershwin ME, Ma X (2017) Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 16(9):885–896PubMedGoogle Scholar
  102. 102.
    Ma HD, Ma WT, Liu QZ, Zhao ZB, Liu MZY, Tsuneyama K, Gao JM, Ridgway WM, Ansari AA, Gershwin ME, Fei YY, Lian ZX (2017) Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation. J Autoimmun 78:19–28PubMedPubMedCentralGoogle Scholar
  103. 103.
    Jaillon S, Berthenet K, and Garlanda C (2017) Sexual dimorphism in innate immunity. Clin Rev Allergy ImmunolGoogle Scholar
  104. 104.
    Margery-Muir AA, Bundell C, Nelson D, Groth DM, Wetherall JD (2017) Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev 16(3):258–268PubMedGoogle Scholar
  105. 105.
    Castaneda S, Gonzalez-Juanatey C, Gonzalez-Gay MA (2017) Sex and cardiovascular involvement in inflammatory joint diseases. Clin Rev Allergy ImmunolGoogle Scholar
  106. 106.
    Ma WT, Chang C, Gershwin ME, Lian ZX (2017) Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun 83:95–112PubMedGoogle Scholar
  107. 107.
    Conrad K, Röber N, Andrade LEC, Mahler M (2017) The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol 52(2):202–216PubMedGoogle Scholar
  108. 108.
    Tozzoli R, Villalta D, Bizzaro N (2017) Challenges in the standardization of autoantibody testing: a comprehensive review. Clin Rev Allergy Immunol 53(1):68–77PubMedGoogle Scholar
  109. 109.
    Takeuchi A, Matsushita T, Kaji K, Okamoto Y, Yasui M, Hirata M, Oishi N, Higashi A, Seishima M, Asano T, Fujimoto M, Kuwana M, Takehara K, Hamaguchi Y (2017) Autoantibody to scaffold attachment factor B (SAFB): a novel connective tissue disease-related autoantibody associated with interstitial lung disease. J Autoimmun 76:101–107PubMedGoogle Scholar
  110. 110.
    Sperotto F, Seguso M, Gallo N, Plebani M, Zulian F (2017) Anti-DFS70 antibodies in healthy schoolchildren: a follow-up analysis. Autoimmun Rev 16(2):210–211PubMedGoogle Scholar
  111. 111.
    Sowa M, Hiemann R, Schierack P, Reinhold D, Conrad K, Roggenbuck D (2017) Next-generation autoantibody testing by combination of screening and confirmation-the CytoBead(R) technology. Clin Rev Allergy Immunol 53(1):87–104PubMedGoogle Scholar
  112. 112.
    Hoxha A, Banzato A, Ruffatti A, Pengo V (2017) Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev 16(2):173–178PubMedGoogle Scholar
  113. 113.
    Novak GV, Marques M, Balbi V, Gormezano NWS, Kozu K, Sakamoto AP, Pereira RMR, Terreri MT, Magalhães CS, Guariento A, Sallum AME, Marini R, Ferriani VPL, Barbosa CM, de Castro TCM, Ramos VC, Bonfá E, Silva CA (2017) Anti-RO/SSA and anti-La/SSB antibodies: association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun Rev 16(2):132–135PubMedGoogle Scholar
  114. 114.
    Reed JH, Gorny MK, Li L, Cardozo T, Buyon JP, Clancy RM (2017) Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. J Autoimmun 79:99–104PubMedPubMedCentralGoogle Scholar
  115. 115.
    Alivernini S, Galeazzi M, Peleg H, Tolusso B, Gremese E, Ferraccioli G, Naparstek Y (2017) Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. Autoimmun Rev 16(11):1096–1102PubMedGoogle Scholar
  116. 116.
    Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, Toes REM, Mahler M, Trouw LA (2017) Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun 80:77–84PubMedGoogle Scholar
  117. 117.
    Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S, Harre U, Ackermann JA, Seefried M, Kleyer A, Uderhardt S, Haugg B, Hueber AJ, Daum P, Heidkamp GF, Ge C, Böhm S, Lux A, Schuh W, Magorivska I, Nandakumar KS, Lönnblom E, Becker C, Dudziak D, Wuhrer M, Rombouts Y, Koeleman CA, Toes R, Winkler TH, Holmdahl R, Herrmann M, Blüml S, Nimmerjahn F, Schett G, Krönke G (2017) Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol 18(1):104–113PubMedGoogle Scholar
  118. 118.
    Dahan S, Segal Y, Watad A, Azrielant S, Shemer A, Maymon D, Stroev YI, Sobolevskaya PA, Korneva EA, Blank M, Gilburd B, Shovman O, Amital H, Ehrenfeld M, Tanay A, Kivity S, Pras E, Chapman J, Damoiseaux J, Cervera R, Putterman C, Shapiro I, Mouthon L, Perricone R, Bizzaro N, Koren O, Riemekasten G, Chereshnev VA, Mazurov VI, Goloviznin M, Gurevich V, Churilov LP, Shoenfeld Y (2017) Novelties in the field of autoimmunity—1st Saint Petersburg congress of autoimmunity, the bridge between east and west. Autoimmun Rev 16(12):1175–1184PubMedGoogle Scholar
  119. 119.
    Doria A, Gatto M, Iaccarino L, Sarzi-Puttini P (2017) Unresolved and critical issues in autoimmune rheumatic diseases. Autoimmun Rev 16(11):1093–1095PubMedGoogle Scholar
  120. 120.
    Generali E, Ceribelli A, Stazi MA, Selmi C (2017) Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun 83:51–61PubMedGoogle Scholar
  121. 121.
    Elieh Ali Komi D and Grauwet K (2017) Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clin Rev Allergy ImmunolGoogle Scholar
  122. 122.
    Ferreira RC, Simons HZ, Thompson WS, Rainbow DB, Yang X, Cutler AJ, Oliveira J, Castro Dopico X, Smyth DJ, Savinykh N, Mashar M, Vyse TJ, Dunger DB, Baxendale H, Chandra A, Wallace C, Todd JA, Wicker LS, Pekalski ML (2017) Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J Autoimmun 84:75–86PubMedPubMedCentralGoogle Scholar
  123. 123.
    Fortner KA, Bond JP, Austin JW, Boss JM, Budd RC (2017) The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns. J Autoimmun 82:47–61PubMedPubMedCentralGoogle Scholar
  124. 124.
    Gattinoni L, Speiser DE, Lichterfeld M, Bonini C (2017) T memory stem cells in health and disease. Nat Med 23(1):18–27PubMedGoogle Scholar
  125. 125.
    Geng J, Yu S, Zhao H, Sun X, Li X, Wang P, Xiong X, Hong L, Xie C, Gao J, Shi Y, Peng J, Johnson RL, Xiao N, Lu L, Han J, Zhou D, Chen L (2017) The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells. Nat Immunol 18(7):800–812PubMedGoogle Scholar
  126. 126.
    Gravina G, Wasén C, Garcia-Bonete MJ, Turkkila M, Erlandsson MC, Töyrä Silfverswärd S, Brisslert M, Pullerits R, Andersson KM, Katona G, Bokarewa MI (2017) Survivin in autoimmune diseases. Autoimmun Rev 16(8):845–855PubMedGoogle Scholar
  127. 127.
    Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T (2017) Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol 18(1):74–85PubMedGoogle Scholar
  128. 128.
    Hemon P, Renaudineau Y, Debant M, le Goux N, Mukherjee S, Brooks W, Mignen O (2017) Calcium signaling: from normal B cell development to tolerance breakdown and autoimmunity. Clin Rev Allergy Immunol 53(2):141–165PubMedGoogle Scholar
  129. 129.
    Iizuka-Koga M, Nakatsukasa H, Ito M, Akanuma T, Lu Q, Yoshimura A (2017) Induction and maintenance of regulatory T cells by transcription factors and epigenetic modifications. J Autoimmun 83:113–121PubMedGoogle Scholar
  130. 130.
    Jamilloux Y, et al (2017) Geoepidemiology and immunologic features of autoinflammatory diseases: a comprehensive review. Clin Rev Allergy ImmunolGoogle Scholar
  131. 131.
    Jorch SK, Kubes P (2017) An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med 23(3):279–287PubMedGoogle Scholar
  132. 132.
    Kaur G, Mohindra K, Singla S (2017) Autoimmunity—basics and link with periodontal disease. Autoimmun Rev 16(1):64–71PubMedGoogle Scholar
  133. 133.
    Lee KH, Kronbichler A, Park DDY, Park YM, Moon H, Kim H, Choi JH, Choi YS, Shim S, Lyu IS, Yun BH, Han Y, Lee D, Lee SY, Yoo BH, Lee KH, Kim TL, Kim H, Shim JS, Nam W, So H, Choi SY, Lee S, Shin JI (2017) Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev 16(11):1160–1173PubMedGoogle Scholar
  134. 134.
    Manthiram K, Zhou Q, Aksentijevich I, Kastner DL (2017) The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 18(8):832–842PubMedGoogle Scholar
  135. 135.
    Mantovani A (2017) Wandering pathways in the regulation of innate immunity and inflammation. J Autoimmun 85:1–5PubMedGoogle Scholar
  136. 136.
    Morell M, Varela N, Maranon C (2017) Myeloid populations in systemic autoimmune diseases. Clin Rev Allergy Immunol 53(2):198–218PubMedGoogle Scholar
  137. 137.
    Oftedal BE, Ardesjö Lundgren B, Hamm D, Gan PY, Holdsworth SR, Hahn CN, Schreiber AW, Scott HS (2017) T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ. J Autoimmun 81:24–33PubMedGoogle Scholar
  138. 138.
    Papp G, Boros P, Nakken B, Szodoray P, Zeher M (2017) Regulatory immune cells and functions in autoimmunity and transplantation immunology. Autoimmun Rev 16(5):435–444PubMedGoogle Scholar
  139. 139.
    Park SH, Kang K, Giannopoulou E, Qiao Y, Kang K, Kim G, Park-Min KH, Ivashkiv LB (2017) Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat Immunol 18(10):1104–1116PubMedPubMedCentralGoogle Scholar
  140. 140.
    Petersen F, Yue X, Riemekasten G, Yu X (2017) Dysregulated homeostasis of target tissues or autoantigens—a novel principle in autoimmunity. Autoimmun Rev 16(6):602–611PubMedGoogle Scholar
  141. 141.
    Picard C, Belot A (2017) Does type-I interferon drive systemic autoimmunity? Autoimmun Rev 16(9):897–902PubMedGoogle Scholar
  142. 142.
    Renaudineau Y (2017) Immunophenotyping as a new tool for classification and monitoring of systemic autoimmune diseases. Clin Rev Allergy Immunol 53(2):177–180PubMedGoogle Scholar
  143. 143.
    Zikherman J, Lowell CA (2017) B cell autoimmunity at the extremes. Nat Immunol 18(10):1065–1066PubMedGoogle Scholar
  144. 144.
    Xiang Z, Yang Y, Chang C, Lu Q (2017) The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J Autoimmun 83:43–50PubMedGoogle Scholar
  145. 145.
    Veldhoen M (2017) Interleukin 17 is a chief orchestrator of immunity. Nat Immunol 18(6):612–621PubMedGoogle Scholar
  146. 146.
    Theofilopoulos AN, Kono DH, Baccala R (2017) The multiple pathways to autoimmunity. Nat Immunol 18(7):716–724PubMedPubMedCentralGoogle Scholar
  147. 147.
    Brooks WH (2017) A review of autoimmune disease hypotheses with introduction of the “nucleolus” hypothesis. Clin Rev Allergy Immunol 52(3):333–350PubMedGoogle Scholar
  148. 148.
    Adorisio S, Fierabracci A, Muscari I, Liberati AM, Ayroldi E, Migliorati G, Thuy TT, Riccardi C, Delfino DV (2017) SUMO proteins: guardians of immune system. J Autoimmun 84:21–28PubMedGoogle Scholar
  149. 149.
    Chen K, Liu J, Cao X (2017) Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun 83:1–11PubMedGoogle Scholar
  150. 150.
    Aune TM, Crooke PS III, Patrick AE, Tossberg JT, Olsen NJ, Spurlock CF III (2017) Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. J Autoimmun 81:99–109PubMedPubMedCentralGoogle Scholar
  151. 151.
    Bansal K, Yoshida H, Benoist C, Mathis D (2017) The transcriptional regulator Aire binds to and activates super-enhancers. Nat Immunol 18(3):263–273PubMedPubMedCentralGoogle Scholar
  152. 152.
    Crowe W, Allsopp PJ, Watson GE, Magee PJ, Strain JJ, Armstrong DJ, Ball E, McSorley EM (2017) Mercury as an environmental stimulus in the development of autoimmunity—a systematic review. Autoimmun Rev 16(1):72–80PubMedGoogle Scholar
  153. 153.
    Watad A, Azrielant S, Bragazzi NL, Sharif K, David P, Katz I, Aljadeff G, Quaresma M, Tanay G, Adawi M, Amital H, Shoenfeld Y (2017) Seasonality and autoimmune diseases: the contribution of the four seasons to the mosaic of autoimmunity. J Autoimmun 82:13–30PubMedGoogle Scholar
  154. 154.
    Qiao YC, Pan YH, Ling W, Tian F, Chen YL, Zhang XX, Zhao HL (2017) The yin and Yang of regulatory T cell and therapy progress in autoimmune disease. Autoimmun Rev 16(10):1058–1070PubMedPubMedCentralGoogle Scholar
  155. 155.
    Chen B, Sun L, Zhang X (2017) Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. J Autoimmun 83:31–42PubMedGoogle Scholar
  156. 156.
    Dutra RC (2017) Kinin receptors: key regulators of autoimmunity. Autoimmun Rev 16(2):192–207PubMedGoogle Scholar
  157. 157.
    Li S, Yang D, Peng T, Wu Y, Tian Z, Ni B (2017) Innate lymphoid cell-derived cytokines in autoimmune diseases. J Autoimmun 83:62–72PubMedGoogle Scholar
  158. 158.
    Al-Soudi A, Kaaij MH, Tas SW (2017) Endothelial cells: from innocent bystanders to active participants in immune responses. Autoimmun Rev 16(9):951–962PubMedGoogle Scholar
  159. 159.
    Coronel-Restrepo N, Posso-Osorio I, Naranjo-Escobar J, Tobón GJ (2017) Autoimmune diseases and their relation with immunological, neurological and endocrinological axes. Autoimmun Rev 16(7):684–692PubMedGoogle Scholar
  160. 160.
    Torres-Ruiz J, Sulli A, Cutolo M, Shoenfeld Y (2017) Air travel, circadian rhythms/hormones, and autoimmunity. Clin Rev Allergy Immunol 53(1):117–125PubMedGoogle Scholar
  161. 161.
    Colotta F, Jansson B, Bonelli F (2017) Modulation of inflammatory and immune responses by vitamin D. J Autoimmun 85:78–97PubMedGoogle Scholar
  162. 162.
    Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L, Abbas F, Abdelmoumni A, Hilliquin P, Requeda E, Adoue D, Brassat D, Agard C, Masseau A, Aladjidi N, Clet J, Fernandes H, Lemasson G, Perel Y, Raymond I, Richer O, Vital A, Allain-Launay E, Bru M, Nicolino M, Thomas C, Altman JJ, Amsallem D, Aras N, Boukari L, Dubrel M, Fain O, Letellier E, Lucidarme N, Mekinian A, Morin AS, Stirnemann J, Atlan C, Audry D, Augustin J, Bakir R, Bartolucci P, Chevalier X, Godeau B, Guillaud C, Khellaf M, Limal N, Lousteau V, Mahevas M, Méliksetyan G, Michel M, Roumier M, Bayart S, Bonnet F, Decaux O, Bekherraz A, Brihaye B, Dachez R, Daugas E, Hayem G, Meyer O, Papo T, Pasqualoni E, Sacre K, Travert F, Bellon H, Beltrand J, Lefrere F, Simon A, Benhamou PY, Benveniste O, Bolgert F, Costedoat-Chalumeau N, de Paz R, Demeret S, Fautrel B, Jacqueminet S, Louapre C, Maillart E, Morel N, Papeix C, Rigabert J, Bensaid P, Berger C, Berquin P, le Moing AG, Berroir S, Besson G, Boutte C, Casez O, Bonnotte B, Audia S, Bossu-Estour C, Bourgarit A, Dupuy A, Keshmandt H, Bourre B, Brac A, Perrin A, Pondarré C, Villar-Fimbel S, Bruckert I, Cosson A, Magy-Bertrand N, Tisserand G, Camu W, Carlander B, Morales RJ, Cances C, Pasquet M, Castilla Lievre MA, Chabroux S, Charif M, Chatelus E, Sibilia J, Chevrant-Breton J, Clavel S, Bille-Turc F, Cohen J, Courcoux MF, Leverger G, Machet L, Cuisset JM, Cony-Makhoul P, Darsy P, Favre S, Giraud P, Leitenschenck L, Monteiro I, Morati C, DeSeze J, Dinulescu M, Dhaoui T, Dommange-Romero F, Drevard E, Dupuis C, Dumuis ML, Durand JM, Farad S, Lecomte P, Pierre P, Fouyssac F, Gaudin P, Gautier A, Gellen-Dautremer J, Jarrin I, Richette P, Georget E, Gras P, Moreau T, Giraud E, Hacini M, Mayer A, Guillaumat C, Guillaume S, Guitton C, Kone-Paut I, Marsaud C, Rossi L, Guyot MH, Hassler P, Heimfert C, Heinzlef O, Hillion B, Hocquelet C, Husson H, Ichai P, Jeziorski E, Deslandre CJ, le Guern V, Kamenov K, Kerlan V, Lemoine P, Misery L, Pan-Petesch B, Krivitzky A, Labauge P, Rodier M, Lacade C, Razafimahefa B, Lachgar K, Larmarau MP, Leblanc T, Lebrun-Frenay C, Lefèbvre P, Lejoyeux P, Leske C, Ly K, Magy L, Mansuy S, Marechaud R, Martin Negrier ML, Sole G, Maupetit J, Mazingue F, Mochon S, Moktar B, Morcamp D, Morlet-Barla N, Nicolas G, Pautot V, Pellier I, Verret JL, Outteryck O, Vermersch P, Pallot-Prades B, Paquet JM, Puechal X, Sortais A, Pelletier J, Rico A, Pez D, Stankoff B, Quittet P, Rémy C, Roba E, Rosario H, Roudaut N, Sonnet E, Ruel M, Sebban S, Schaepelynck P, Simonin MJ, Vial C, Viallard JF, Ladedan I, Zenone T (2017) Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance. J Autoimmun 79:84–90PubMedGoogle Scholar
  163. 163.
    De Groof A et al (2017) Dysregulated lymphoid cell populations in mouse models of systemic lupus erythematosus. Clin Rev Allergy Immunol 53(2):181–197PubMedGoogle Scholar
  164. 164.
    Choi JY, Seth A, Kashgarian M, Terrillon S, Fung E, Huang L, Wang LC, Craft J (2017) Disruption of pathogenic cellular networks by IL-21 blockade leads to disease amelioration in murine lupus. J Immunol 198(7):2578–2588PubMedPubMedCentralGoogle Scholar
  165. 165.
    Dai H, He F, Tsokos GC, Kyttaris VC (2017) IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J Immunol 199(3):903–910PubMedPubMedCentralGoogle Scholar
  166. 166.
    Goropevsek A, Holcar M, Avcin T (2017) The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol 52(2):164–181PubMedGoogle Scholar
  167. 167.
    Bird AK, Chang M, Barnard J, Goldman BI, Meednu N, Rangel-Moreno J, Anolik JH (2017) Neutrophils slow disease progression in murine lupus via modulation of autoreactive germinal centers. J Immunol 199(2):458–466PubMedPubMedCentralGoogle Scholar
  168. 168.
    Bakshi J, Segura BT, Wincup C, Rahman A (2017) Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy ImmunolGoogle Scholar
  169. 169.
    Giannelou M, Mavragani CP (2017) Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun 82:1–12PubMedGoogle Scholar
  170. 170.
    Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A (2017) Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmun Rev 16(3):308–312PubMedGoogle Scholar
  171. 171.
    Buie JJ, Renaud LL, Muise-Helmericks R, Oates JC (2017) IFN-alpha negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus. J Immunol 199(6):1979–1988PubMedPubMedCentralGoogle Scholar
  172. 172.
    Bundhun PK, Soogund MZ, Huang F (2017) Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001-2016. J Autoimmun 79:17–27PubMedGoogle Scholar
  173. 173.
    Gianfreda D, Quaglini S, Frontini G, Raffiotta F, Messa P, Moroni G (2017) Does pregnancy have any impact on long term damage accrual and on the outcome of lupus nephritis? J Autoimmun 84:46–54PubMedGoogle Scholar
  174. 174.
    Yousef Yengej FA, van Royen-Kerkhof A, Derksen RHWM, Fritsch-Stork RDE (2017) The development of offspring from mothers with systemic lupus erythematosus. A systematic review. Autoimmun Rev 16(7):701–711PubMedGoogle Scholar
  175. 175.
    Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, Saenz R, Richez C, Porta S, Blanco P (2017) Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 16(8):826–832PubMedGoogle Scholar
  176. 176.
    Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I (2017) Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev 16(4):343–351PubMedGoogle Scholar
  177. 177.
    Kleinmann JF, Tubach F, le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg JE (2017) International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev 16(6):650–657PubMedGoogle Scholar
  178. 178.
    Kronbichler A, Windpessl M, Pieringer H, Jayne DRW (2017) Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev 16(6):633–643PubMedGoogle Scholar
  179. 179.
    Zampeli E, Klinman DM, Gershwin ME, Moutsopoulos HM (2017) A comprehensive evaluation for the treatment of lupus nephritis. J Autoimmun 78:1–10PubMedGoogle Scholar
  180. 180.
    Ribero S, Sciascia S, Borradori L, Lipsker D (2017) The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol 53(3):291–305PubMedGoogle Scholar
  181. 181.
    Sciascia S, Radin M, Yazdany J, Levy RA, Roccatello D, Dall'Era M, Cuadrado MJ (2017) Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev 16(3):287–293PubMedGoogle Scholar
  182. 182.
    Narain S, Furie R (2016) Update on clinical trials in systemic lupus erythematosus. Curr Opin Rheumatol 28(5):477–487PubMedGoogle Scholar
  183. 183.
    Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74(11):2006–2015PubMedGoogle Scholar
  184. 184.
    Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D, on behalf of the ADDRESS II Investigators (2018) Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol 70(2):266–276PubMedPubMedCentralGoogle Scholar
  185. 185.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS (2018) Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77(6):883–889PubMedGoogle Scholar
  186. 186.
    Isenberg D (2016) Further thoughts about the ILLUMINATE studies of tabalumab in SLE. Ann Rheum Dis 75(2):e11PubMedGoogle Scholar
  187. 187.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75(2):323–331PubMedGoogle Scholar
  188. 188.
    Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379PubMedGoogle Scholar
  189. 189.
    Doria A, Cervera R, Gatto M, Chehab G, Schneider M (2017) The new targeted therapy in systemic lupus erythematosus: is the glass half-full or half-empty? Autoimmun Rev 16(11):1119–1124PubMedGoogle Scholar
  190. 190.
    Du FH, Mills EA, Mao-Draayer Y (2017) Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights 8(1):12PubMedPubMedCentralGoogle Scholar
  191. 191.
    Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ (2017) Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) 56(7):1227–1237Google Scholar
  192. 192.
    Baker KF, Isaacs JD (2018) Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis 77(2):175–187PubMedGoogle Scholar
  193. 193.
    Favoino E, Prete M, Marzullo A, Millo E, Shoenfeld Y, Perosa F (2017) CD20-mimotope peptide active immunotherapy in systemic lupus erythematosus and a reappraisal of vaccination strategies in rheumatic diseases. Clin Rev Allergy Immunol 52(2):217–233PubMedGoogle Scholar
  194. 194.
    Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y (2017) Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients. J Immunol 198(8):3069–3080PubMedPubMedCentralGoogle Scholar
  195. 195.
    Dudhgaonkar S, Ranade S, Nagar J, Subramani S, Prasad DS, Karunanithi P, Srivastava R, Venkatesh K, Selvam S, Krishnamurthy P, Mariappan TT, Saxena A, Fan L, Stetsko DK, Holloway DA, Li X, Zhu J, Yang WP, Ruepp S, Nair S, Santella J, Duncia J, Hynes J, McIntyre KW, Carman JA (2017) Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity. J Immunol 198(3):1308–1319PubMedPubMedCentralGoogle Scholar
  196. 196.
    Leone A, Radin M, Almarzooqi AM, al-Saleh J, Roccatello D, Sciascia S, Khamashta M (2017) Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 16(5):469–477PubMedGoogle Scholar
  197. 197.
    Salman-Monte TC, Torrente-Segarra V, Vega-Vidal AL, Corzo P, Castro-Dominguez F, Ojeda F, Carbonell-Abelló J (2017) Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): a systematic review. Autoimmun Rev 16(11):1155–1159PubMedGoogle Scholar
  198. 198.
    Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, Shahrara S (2017) TLRs, future potential therapeutic targets for RA. Autoimmun Rev 16(2):103–113PubMedGoogle Scholar
  199. 199.
    Amara K, Clay E, Yeo L, Ramsköld D, Spengler J, Sippl N, Cameron JA, Israelsson L, Titcombe PJ, Grönwall C, Sahbudin I, Filer A, Raza K, Malmström V, Scheel-Toellner D (2017) B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis. J Autoimmun 81:34–43PubMedPubMedCentralGoogle Scholar
  200. 200.
    Banko Z et al (2017) Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients. J Immunol 198(4):1512–1520PubMedGoogle Scholar
  201. 201.
    Hu F, Liu H, Liu X, Zhang X, Xu L, Zhu H, Li Y, Shi L, Ren L, Zhang J, Li Z, Jia Y (2017) Pathogenic conversion of regulatory B10 cells into osteoclast-priming cells in rheumatoid arthritis. J Autoimmun 76:53–62PubMedGoogle Scholar
  202. 202.
    Zamora C, Cantó E, Nieto JC, Bardina J, Diaz-Torné C, Moya P, Magallares B, Ortiz MA, Julià G, Juarez C, Llobet JM, Vidal S (2017) Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis. J Immunol 198(8):3099–3108PubMedGoogle Scholar
  203. 203.
    Wasen C et al (2017) Smoking activates cytotoxic CD8(+) T cells and causes survivin release in rheumatoid arthritis. J Autoimmun 78:101–110PubMedGoogle Scholar
  204. 204.
    Vojinovic J, Tincani A, Sulli A, Soldano S, Andreoli L, Dall'Ara F, Ionescu R, Pasalic KS, Balcune I, Ferraz-Amaro I, Tlustochowicz M, Butrimiene I, Punceviciene E, Toroptsova N, Grazio S, Morovic-Vergles J, Masaryk P, Otsa K, Bernardes M, Boyadzhieva V, Salaffi F, Cutolo M (2017) European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO). Autoimmun Rev 16(5):548–554PubMedGoogle Scholar
  205. 205.
    Ishikawa LLW, Colavite PM, Fraga-Silva TFC, Mimura LAN, França TGD, Zorzella-Pezavento SFG, Chiuso-Minicucci F, Marcolino LD, Penitenti M, Ikoma MRV, Sartori A (2017) Vitamin D deficiency and rheumatoid arthritis. Clin Rev Allergy Immunol 52(3):373–388PubMedGoogle Scholar
  206. 206.
    Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R (2017) The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev 16(12):1185–1195PubMedGoogle Scholar
  207. 207.
    Bystrom J, Clanchy FI, Taher TE, al-Bogami MM, Muhammad HA, Alzabin S, Mangat P, Jawad AS, Williams RO, Mageed RA (2017) Response to treatment with TNFalpha inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes. Clin Rev Allergy Immunol 53(2):265–276PubMedPubMedCentralGoogle Scholar
  208. 208.
    Gazeau P, Alegria GC, Devauchelle-Pensec V, Jamin C, Lemerle J, Bendaoud B, Brooks WH, Saraux A, Cornec D, Renaudineau Y (2017) Memory B cells and response to abatacept in rheumatoid arthritis. Clin Rev Allergy Immunol 53(2):166–176PubMedGoogle Scholar
  209. 209.
    Perez-Sanchez C et al (2017) Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in rheumatoid arthritis patients. J Autoimmun 82:31–40PubMedGoogle Scholar
  210. 210.
    Sandigursky S, Silverman GJ, Mor A (2017) Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Autoimmun Rev 16(8):767–773PubMedPubMedCentralGoogle Scholar
  211. 211.
    Elieh Ali Komi D, Shafaghat F, Zwiener RD (2017) Immunology of bee venom. Clin Rev Allergy ImmunolGoogle Scholar
  212. 212.
    Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, Vandecasteele E, de Keyser F, Distler O, Gutermuth J, Smith V (2017) The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev 16(8):774–786PubMedGoogle Scholar
  213. 213.
    Cossu M, Beretta L, Mosterman P, de Hair MJH, Radstake TRDJ (2017) Unmet needs in systemic sclerosis understanding and treatment: the knowledge gaps from a scientist’s, clinician’s, and patient’s perspective. Clin Rev Allergy ImmunolGoogle Scholar
  214. 214.
    Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L (2017) Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol 53(3):306–336PubMedGoogle Scholar
  215. 215.
    Soulaidopoulos S, Triantafyllidou E, Garyfallos A, Kitas GD, Dimitroulas T (2017) The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: a critical review. Autoimmun Rev 16(8):787–795PubMedGoogle Scholar
  216. 216.
    Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, Bravard P, Noël D, Cailleux AF, Benichou J, Levesque H, Goullé JP (2017) Systemic sclerosis and exposure to heavy metals: a case control study of 100 patients and 300 controls. Autoimmun Rev 16(3):223–230PubMedGoogle Scholar
  217. 217.
    Tsou PS, Sawalha AH (2017) Unfolding the pathogenesis of scleroderma through genomics and epigenomics. J Autoimmun 83:73–94PubMedPubMedCentralGoogle Scholar
  218. 218.
    Slobodin G, Rimar D (2017) Regulatory T cells in systemic sclerosis: a comprehensive review. Clin Rev Allergy Immunol 52(2):194–201PubMedGoogle Scholar
  219. 219.
    Berger M, Steen VD (2017) Role of anti-receptor autoantibodies in pathophysiology of scleroderma. Autoimmun Rev 16(10):1029–1035PubMedGoogle Scholar
  220. 220.
    Sanges S, Rivière S, Mekinian A, Martin T, le Quellec A, Chatelus E, Lescoat A, Jego P, Cazalets C, Quéméneur T, le Gouellec N, Senet P, Francès C, Deroux A, Imbert B, Fain O, Boukari L, Sené T, Deligny C, Mathian A, Agard C, Pugnet G, Speca S, Dubucquoi S, Hatron PY, Hachulla É, Launay D (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 16(4):377–384PubMedGoogle Scholar
  221. 221.
    Rossi D, Zanatta E, Marson P, Sciascia S, Polito P, Roccatello D, Cozzi F (2017) How I treat patients with systemic sclerosis in clinical practice. Autoimmun Rev 16(10):1024–1028PubMedGoogle Scholar
  222. 222.
    Giat E, Ehrenfeld M, Shoenfeld Y (2017) Cancer and autoimmune diseases. Autoimmun Rev 16(10):1049–1057PubMedGoogle Scholar
  223. 223.
    Boonstra M, Huizinga TWJ, de Vries-Bouwstra JK (2017) Auto-antibodies and cancer in systemic sclerosis. Autoimmun Rev 16(8):883–884PubMedGoogle Scholar
  224. 224.
    Bernal-Bello D, de Tena JG, Guillén-del Castillo A, Selva-O’Callaghan A, Callejas-Moraga EL, Marín-Sánchez AM, Fonollosa-Pla V, Simeón-Aznar CP (2017) Novel risk factors related to cancer in scleroderma. Autoimmun Rev 16(5):461–468PubMedGoogle Scholar
  225. 225.
    Wu J, Li X, Song W, Fang Y, Yu L, Liu S, Churilov LP, Zhang F (2017) The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. Autoimmun Rev 16(12):1270–1281PubMedGoogle Scholar
  226. 226.
    June CH, Warshauer JT, Bluestone JA (2017) Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 23(5):540–547PubMedGoogle Scholar
  227. 227.
    He XS, Gershwin ME, Ansari AA (2017) Checkpoint-based immunotherapy for autoimmune diseases—opportunities and challenges. J Autoimmun 79:1–3PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Rheumatology and Clinical ImmunologyHumanitas Research HospitalMilanItaly
  2. 2.BIOMETRA DepartmentUniversity of MilanMilanItaly

Personalised recommendations